Who are adalimumab (D2E7)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Humira, Abrilada, Etanercept + Methotrexate, TNF Inhibitor, Tapered doses of TNFi, Certolizumab Pegol (CZP).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/adalimumab-d2e7.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

adalimumab (D2E7) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

adalimumab (D2E7) (adalimumab (D2E7)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TNF inhibitor. Area: Immunology.

phase 3 TNF inhibitor TNF-alpha Immunology Biologic Live · refreshed every 30 min

Target snapshot

adalimumab (D2E7) (adalimumab (D2E7)) — Abbott. Adalimumab is a fully human monoclonal antibody that selectively binds to tumor necrosis factor-alpha (TNF-alpha), preventing its interaction with cell surface TNF receptors.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
adalimumab (D2E7) TARGET	adalimumab (D2E7)	Abbott	phase 3	TNF inhibitor	TNF-alpha
Humira	ADALIMUMAB	AbbVie	marketed	TNF blocker	Tumor Necrosis Factor-alpha (TNF-alpha)	2002-01-01
Abrilada	Adalimumab-Afzb	AbbVie	marketed	TNF blocker	Tumor necrosis factor-alpha (TNF-alpha)	2002-01-01
Etanercept + Methotrexate	Etanercept + Methotrexate	Wyeth is now a wholly owned subsidiary of Pfizer	marketed	TNF inhibitor + DMARD combination	TNF-alpha receptor (etanercept); dihydrofolate reductase (methotrexate)
TNF Inhibitor	tnf-inhibitor	Pfizer	marketed	Monoclonal Antibody	TNF-alpha
Tapered doses of TNFi	Tapered doses of TNFi	University Health Network, Toronto	marketed	TNF inhibitor (tapered dosing strategy)	TNF-alpha
Certolizumab Pegol (CZP)	Certolizumab Pegol (CZP)	UCB Pharma	marketed	TNF-alpha inhibitor	TNF-alpha

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TNF inhibitor class)

University Hospital, Montpellier · 2 drugs in this class
Amgen · 1 drug in this class
Biogen · 1 drug in this class
Centre Hospitalier Universitaire de Saint Etienne · 1 drug in this class
National Eye Institute (NEI) · 1 drug in this class
Abbott · 1 drug in this class
Spanish Clinical Pharmacology Society · 1 drug in this class
Takeda · 1 drug in this class
University Health Network, Toronto · 1 drug in this class
University Hospital, Ghent · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). adalimumab (D2E7) — Competitive Intelligence Brief. https://druglandscape.com/ci/adalimumab-d2e7. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing